

【4-9 メタアナリシス】

<b>CQ</b>		HER2陽性転移・再発乳癌に対する二次治療で推奨される治療は何か？																												
<b>P</b>	進行再発 HER2陽性乳癌 二次治療	<b>I</b>	抗HER2薬を含んだ併用療法																											
<b>C</b>	Lapatinib or Capecitabine単独治療	<b>O</b>	OS																											
<b>研究デザイン</b>	RCT	<b>文献数</b>	3	<b>コード</b>	EGF104900,EGF100151,GBG 26/BIG 3-05																									
<b>モデル</b>	ランダム効果	<b>方法</b>	Inverse-variance method(RevMan5.3)																											
<b>効果指標</b>	リスク比	<b>統合値</b>	0.83 ( 0.72 - 0.92 ) P= 0.02																											
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> </tr> </thead> <tbody> <tr> <td>EGF100151 2010</td> <td>-0.1393</td> <td>0.1109</td> <td>49.0%</td> <td>0.87 [0.70, 1.08]</td> </tr> <tr> <td>EGF104900 2012</td> <td>-0.3011</td> <td>0.1332</td> <td>34.0%</td> <td>0.74 [0.57, 0.96]</td> </tr> <tr> <td>GBG 26/BIG 3-05 2011</td> <td>-0.0619</td> <td>0.1882</td> <td>17.0%</td> <td>0.94 [0.65, 1.36]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>0.83 [0.72, 0.97]</b></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 1.35, df = 2 (P = 0.51); I<sup>2</sup> = 0% Test for overall effect: Z = 2.33 (P = 0.02)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	EGF100151 2010	-0.1393	0.1109	49.0%	0.87 [0.70, 1.08]	EGF104900 2012	-0.3011	0.1332	34.0%	0.74 [0.57, 0.96]	GBG 26/BIG 3-05 2011	-0.0619	0.1882	17.0%	0.94 [0.65, 1.36]	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.83 [0.72, 0.97]</b>	
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI																									
EGF100151 2010	-0.1393	0.1109	49.0%	0.87 [0.70, 1.08]																										
EGF104900 2012	-0.3011	0.1332	34.0%	0.74 [0.57, 0.96]																										
GBG 26/BIG 3-05 2011	-0.0619	0.1882	17.0%	0.94 [0.65, 1.36]																										
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.83 [0.72, 0.97]</b>																										
コメント:																														
<b>Funnel plot</b>																														
	コメント:																													
<b>その他の解析</b>					コメント:																									
メタリグレーション																														
感度分析																														

【4-9 メタアナリシス】

<b>CQ</b>		HER2陽性転移・再発乳癌に対する二次治療で推奨される治療は何か？																														
<b>P</b>	進行再発 HER2陽性乳癌 二次治療	<b>I</b>	抗HER2薬を含んだ併用療法																													
<b>C</b>	Lapatinib or Capecitabine単独治療	<b>O</b>	PFS																													
<b>研究デザイン</b>	RCT	<b>文献数</b>	3	<b>コード</b>	EGF104900,EGF100151,GBG 26/BIG 3-05																											
<b>モデル</b>	ランダム効果	<b>方法</b>	Inverse-variance method(RevMan5.3)																													
<b>効果指標</b>	リスク比	<b>統合値</b>	0.67 ( 0.56 - 0.92 ) P= <0.0001																													
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> </tr> </thead> <tbody> <tr> <td>EGF100151 2010</td> <td>-0.5978</td> <td>0.1625</td> <td>28.2%</td> <td>0.55 [0.40, 0.76]</td> <td rowspan="4"> </td> </tr> <tr> <td>EGF104900 2012</td> <td>-0.3011</td> <td>0.1243</td> <td>48.2%</td> <td>0.74 [0.58, 0.94]</td> </tr> <tr> <td>GBG 26/BIG 3-05 2011</td> <td>-0.3857</td> <td>0.1777</td> <td>23.6%</td> <td>0.68 [0.48, 0.96]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>0.67 [0.56, 0.79]</b></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 2.12, df = 2 (P = 0.35); I<sup>2</sup> = 6%            Test for overall effect: Z = 4.69 (P &lt; 0.00001)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Hazard Ratio IV, Fixed, 95% CI	EGF100151 2010	-0.5978	0.1625	28.2%	0.55 [0.40, 0.76]		EGF104900 2012	-0.3011	0.1243	48.2%	0.74 [0.58, 0.94]	GBG 26/BIG 3-05 2011	-0.3857	0.1777	23.6%	0.68 [0.48, 0.96]	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.67 [0.56, 0.79]</b>
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Fixed, 95% CI	Hazard Ratio IV, Fixed, 95% CI																										
EGF100151 2010	-0.5978	0.1625	28.2%	0.55 [0.40, 0.76]																												
EGF104900 2012	-0.3011	0.1243	48.2%	0.74 [0.58, 0.94]																												
GBG 26/BIG 3-05 2011	-0.3857	0.1777	23.6%	0.68 [0.48, 0.96]																												
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.67 [0.56, 0.79]</b>																												
<b>コメント:</b>																																
<b>Funnel plot</b>																																
	<b>コメント:</b>																															
<b>その他の解析</b>					<b>コメント:</b>																											
メタリグレーション																																
感度分析																																

【4-9 メタアナリシス】

<b>CQ</b>		HER2陽性転移・再発乳癌に対する二次治療で推奨される治療は何か？																																																											
<b>P</b>	進行再発 HER2陽性乳癌 二次治療	<b>I</b>	抗HER2薬を含んだ併用療法																																																										
<b>C</b>	Lapatinib or Capecitabine単独治療	<b>O</b>	心毒性																																																										
<b>研究デザイン</b>	RCT	<b>文献数</b>	3	<b>コード</b>	EGF104900,EGF100151,GBG 26/BIG 3-05																																																								
<b>モデル</b>	ランダム効果	<b>方法</b>	Mantel;Haenszel method(RevMan5.3)																																																										
<b>効果指標</b>	RR	<b>統合値</b>	2.22 ( 0.76 - 6.5 ) P= 0.14																																																										
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>Experimental Events</th> <th>Experimental Total</th> <th>Control Events</th> <th>Control Total</th> <th>Weight</th> <th>Risk Ratio M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>EGF100151 2010</td> <td>4</td> <td>207</td> <td>4</td> <td>201</td> <td>41.6%</td> <td>0.97 [0.25, 3.83]</td> </tr> <tr> <td>EGF104900 2012</td> <td>10</td> <td>149</td> <td>3</td> <td>146</td> <td>46.1%</td> <td>3.27 [0.92, 11.63]</td> </tr> <tr> <td>GBG 26/BIG 3-05 2011</td> <td>4</td> <td>77</td> <td>0</td> <td>74</td> <td>12.3%</td> <td>8.65 [0.47, 157.99]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>433</b></td> <td></td> <td><b>421</b></td> <td><b>100.0%</b></td> <td><b>2.22 [0.76, 6.50]</b></td> </tr> <tr> <td>Total events</td> <td>18</td> <td></td> <td>7</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="7">Heterogeneity: Tau<sup>2</sup> = 0.23; Chi<sup>2</sup> = 2.65, df = 2 (P = 0.27); I<sup>2</sup> = 24%</td> </tr> <tr> <td colspan="7">Test for overall effect: Z = 1.46 (P = 0.14)</td> </tr> </tbody> </table>				Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Risk Ratio M-H, Random, 95% CI	EGF100151 2010	4	207	4	201	41.6%	0.97 [0.25, 3.83]	EGF104900 2012	10	149	3	146	46.1%	3.27 [0.92, 11.63]	GBG 26/BIG 3-05 2011	4	77	0	74	12.3%	8.65 [0.47, 157.99]	<b>Total (95% CI)</b>		<b>433</b>		<b>421</b>	<b>100.0%</b>	<b>2.22 [0.76, 6.50]</b>	Total events	18		7				Heterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 2.65, df = 2 (P = 0.27); I <sup>2</sup> = 24%							Test for overall effect: Z = 1.46 (P = 0.14)							
Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Risk Ratio M-H, Random, 95% CI																																																							
EGF100151 2010	4	207	4	201	41.6%	0.97 [0.25, 3.83]																																																							
EGF104900 2012	10	149	3	146	46.1%	3.27 [0.92, 11.63]																																																							
GBG 26/BIG 3-05 2011	4	77	0	74	12.3%	8.65 [0.47, 157.99]																																																							
<b>Total (95% CI)</b>		<b>433</b>		<b>421</b>	<b>100.0%</b>	<b>2.22 [0.76, 6.50]</b>																																																							
Total events	18		7																																																										
Heterogeneity: Tau <sup>2</sup> = 0.23; Chi <sup>2</sup> = 2.65, df = 2 (P = 0.27); I <sup>2</sup> = 24%																																																													
Test for overall effect: Z = 1.46 (P = 0.14)																																																													
	コメント:																																																												
<b>Funnel plot</b>																																																													
	コメント:																																																												
<b>その他の解析</b>					コメント:																																																								
メタリグレーション																																																													
感度分析																																																													